Protein expression of prognostic genes in primary melanoma and benign nevi
暂无分享,去创建一个
T. Brüning | T. Gambichler | E. Stockfleth | H. Käfferlein | T. Meyer | L. Susok | M. Skrygan | S. Schröder | K. Lang | M. Nick | D. Wagener | J. Elfering | S. Bruckmüller
[1] Wang Xiaoyuan,et al. Identification of prognostic genes and construction of a novel gene signature in the skin melanoma based on the tumor microenvironment , 2021, Medicine.
[2] J. Becker,et al. Expression of Mismatch Repair Proteins in Merkel Cell Carcinoma , 2021, Cancers.
[3] T. Gambichler,et al. Caucasians with acral lentiginous melanoma have the same outcome as patients with stage- and limb-matched superficial spreading melanoma , 2021, Journal of Cancer Research and Clinical Oncology.
[4] T. Gambichler,et al. Multivariate analysis of prognostic factors in patients with nodular melanoma , 2021, Journal of Cancer Research and Clinical Oncology.
[5] Nuno A. Fonseca,et al. Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study , 2020, bioRxiv.
[6] A. Hauschild,et al. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients. , 2020, European Journal of Cancer.
[7] C. Slingluff,et al. Gene expression analysis in formalin fixed paraffin embedded melanomas is associated with density of corresponding immune cells in those tissues , 2020, Scientific Reports.
[8] M. Boyano,et al. Serum markers improve current prediction of metastasis development in early‐stage melanoma patients: a machine learning‐based study , 2020, Molecular oncology.
[9] Dennis H. Murphree,et al. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model. , 2020, European journal of cancer.
[10] J. Shao,et al. Identification of a Gene-Related Risk Signature in Melanoma Patients Using Bioinformatic Profiling , 2020, Journal of oncology.
[11] Nhat Anh Cao,et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. , 2020, Journal of American Academy of Dermatology.
[12] Lai Xu,et al. NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes , 2020, Frontiers in Immunology.
[13] C. Garbe,et al. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma. , 2019, European journal of cancer.
[14] S. Swetter,et al. Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice , 2019, Melanoma management.
[15] C. Berking,et al. A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging , 2018, JNCI cancer spectrum.
[16] Jeffrey E Gershenwald,et al. Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.
[17] A. Hauschild,et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.
[18] P. Ascierto,et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.
[19] F. Edfors,et al. Gene‐specific correlation of RNA and protein levels in human cells and tissues , 2016, Molecular systems biology.
[20] I. M. de la Fuente,et al. Vitronectin and dermcidin serum levels predict the metastatic progression of AJCC I–II early‐stage melanoma , 2016, International journal of cancer.
[21] V. Gotlieb,et al. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond. , 2016, Critical reviews in oncology/hematology.
[22] I. Osman,et al. Revisiting determinants of prognosis in cutaneous melanoma , 2015, Cancer.
[23] V. Anne Smith,et al. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system , 2015 .
[24] L. Ferris,et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. , 2015, Journal of the American Academy of Dermatology.
[25] Dirk Schadendorf,et al. Melanoma in 2013: Melanoma—the run of success continues , 2014, Nature Reviews Clinical Oncology.
[26] L. Chin,et al. HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome , 2013, Oncogene.
[27] C. Berking,et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma , 2013, Journal of Cancer Research and Clinical Oncology.
[28] S. Wagner,et al. An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma , 2012, PloS one.
[29] C. Robert,et al. New drugs in melanoma: it's a whole new world. , 2011, European journal of cancer.
[30] D. Bishop,et al. Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free Survival , 2009, Clinical Cancer Research.
[31] Yaguang Xi,et al. The impact of genomics in understanding human melanoma progression and metastasis. , 2008, Cancer control : journal of the Moffitt Cancer Center.
[32] M. Nosrati,et al. Osteopontin as a molecular prognostic marker for melanoma , 2008, Cancer.
[33] A. Eggermont,et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. , 2006, Journal of the National Cancer Institute.
[34] K. Hoek,et al. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas , 2005, Cancer biology & therapy.